Attana inks microsampling collaboration with Capitainer for improved diagnostic sampling
Combining Attana’s advanced biosensor system with Capitainer’s DBS home sampling makes immune profiling and vaccine efficacy monitoring possible in broad patient populations.Swedish bio- and healthtech companies Attana AB and Capitainer AB have signed an agreement with the goal of offering broader and more patient-centric blood sampling solutions for the Attana AVA[TM] system starting with COVID-19 immune profiling.
Since November 2021, Attana has been performing comparative studies of finger stick capillary blood samples simultaneously collected by both test tubes and Capitainer®qDBS
Attana has received its first order for the newly launched Attana Cell™ 250 instrument. The order has been placed from an existing pharma customer headquartered in Europe and is the result of several successful contract research projects initiated in the spring of 2018.In March 2018, Attana announced the order of a smaller contract research project from a global pharma company. Following the success of several smaller research projects the customer has today placed an order for an Attana Cell™ 250 instrument. The order will affect the company’s cashflow and earnings in Q4 2020 and Q1 2021.